BIODESIX, INC. (BDSX) reported strong top-line growth in Q3 Fiscal 2025, though the company remains unprofitable. Total revenue reached \(59.7M YTD (up 17.4%), with Q3 revenue at \)21.8M (up 20%), driven by 16% growth in Diagnostic Tests and 97% growth in Development Services. The Net Loss narrowed YTD to \((31.3M)\) from \((34.7M)\) in the prior year, and diluted Loss Per Share improved to \((4.24)\). Cash reserves fell to \(16.6M, offset slightly by \)5.0M in net ATM proceeds.
Management enacted a critical 1-for-20 Reverse Stock Split on September 15, 2025, successfully regaining Nasdaq complianc
...